EULAR 2017 – Day 3 Highlights

Save

Friday was a mega-day in Madrid as this day all the late-breaking abstracts were presented, in addition to the bulk of high-impact podium presentations in several areas.

Here are the major presentations from several clinical areas.

EULAR 2017 – Day 1 Highlights

Save

The Annual EULAR Congress kicked off this afternoon in Madrid with a number of new sessions devoted to important topics. 

Lancet Launches EULAR 2017 and "A Platinum Age of Rheumatology"

Save

The current Lancet edition for 10 June 2017 is a rheumatology rich collection.  

Supreme Court Decision Favors Earlier Biosimilar Adoption

Save

On Monday June 11th, the US Supreme Court unanimously ruled that biosimilar manufacturers can bring their drugs to market faster by eliminating the provision that the biosimar manufacturer had to give the innovator company 180 days notice before launching the new biosimilar.

Biosimilar Reports – May 2017

Save

Biosimilars continue to command a great deal of research, development and attention given the promise of significant cost savings and potentially wider use for those in need. Biosimilar Reports is an ongoing series dedicated to advances, discussions and developments in biosimilar agents intended for use by rheumatologists. 

Golimumab Fails in Polyarticular Juvenile Arthritis

Save

Treatment options for children with active polyarticular juvenile idiopathic arthritis (polyJIA) have lagged behind that seen with adult rheumatoid arthritis.

Biologics Before Triple DMARD is Not Cost Effective in Rheumatoid Arthritis

Save

Stepping up to biologic therapy when methotrexate (MTX) monotherapy fails was not shown to be cost effective, compared to first trying triple therapy, in a rheumatoid arthritis (RA) study published in Annals of Internal Medicine.

The RheumNow Week in Review - 26 May 2017

Save

Dr. Jack Cush Reviews highlights from the past week on RheumNow.com:

Inflammatory Arthritis Stable after Switch to Biosimilar Infliximab

Save

The DANBIO registrys has demonstrated that switching from infliximab (Remicade) to biosimilar CT-P13 (Inflectra in the U.S., Remsima in Europe) does not appear to have any negative effect on inflammatory arthritis disease activity, Danish researchers reported.

Educational Intervention Facilitates Treat-to-Target Management in Rheumatoid Arthritis

Save

Treat-to-target education through group-based quality improvement sessions can result in wider use of treat-to-target in practice, according to researchers.

NOR-SWITCH Study Validates Biosimilar Use in Multiple Indications

Save

Lancet reports the results of the NOR-SWITCH study - a trial performed in Norway as biosimilars were being introduced.

The RheumNow Week in Review – 12 May 2017

Save

Dr. Jack Cush highlights the big stories, news and articles from this week at RheumNow.com.

Adalimumab Effective in Pediatric Plaque Psoriasis

Save

Adalimumab is currently FDA approved for use in adult psoriasis, pediatric Crohn's disease and polyarticular juvenile idiopathic arthritis.  The current Lancet trial assesses the efficacy and safety of adalimumab in children and adolescents with severe plaque psoriasis.

Above-Label Dosing and Noncompliance with Biologics in Psoriatic Arthritis

Save

Claims data analysis of 4245 psoriatic arthritis patients on TNF inhibitors showed both higher than expected durations of noncompliance and higher than label dosing - all at an increased cost.

The RheumNow Week in Review – 28 April 2017

Save

Dr. Jack Cush reviews the news from the last week on RheumNow.com - from the ACR SOTA 2017 meeting in Chicago:

Pregnancy Flares in RA and Spondylitis

Save

Despite the folklore, not all women with arthritis who become pregnant will improve or go into remission.  Recent studies have suggested that up to one-third of RA patients will flare during pregnancy.

FDA Approves Renflexis as Second Infliximab Biosimilar

Save

On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD.  In early developmental trials this agent was also called SB2.

Paradoxical Toxicities with TNF Inhibitors

Save

Something is curiously wrong when a drug induces the disease it is intended to treat. Yet this phenomenon has been described with all five FDA-approved TNF inhibitors.

Inconsistent ESR & CRP in Spondylitis Patients

Save

Patients with active axial spondyloarthritis (axSpA) can lack evidence of inflammation on magnetic resonance imaging (MRI) but may develop evidence of inflammation over time.